Registry for managing Helicobacter pylori infection in Shandong Province

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a non-interventional, multi-center patient registry collecting clinical, treatment, and follow-up data from adults with confirmed H. pylori infection treated at participating hospitals in Shandong Province. Treating physicians will prescribe guideline-recommended regimens (for example, 14-day high-dose amoxicillin dual therapy or bismuth-containing quadruple therapy) tailored to each patient, while the registry records outcomes, adverse events, and costs. The database will also capture factors that influence eradication success such as smoking status, body surface area, CYP2C19 genotypes, patient adherence, and regional antibiotic resistance patterns. Analyses will compare effectiveness, safety, and cost-effectiveness of different real-world therapeutic strategies without altering usual clinical care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* patients aged 18-80 years, regardless of gender;
* willing to receive H. pylori eradication therapy;
* diagnosed with H. pylori infection through at least one of the following methods: rapid urease test, ¹³C/¹⁴C-urea breath test, or histopathological examination.

Exclusion Criteria:

* patients with incomplete medical records, including missing treatment details, absence of post-treatment follow-up test results, or failure to complete essential follow-up assessments;
* patients with severe underlying conditions such as hepatic insufficiency, renal insufficiency, or malignant tumours;
* pregnant or breastfeeding women;
* individuals who refuse to sign the informed consent form

Where it's running

• Qilu Hospital of Shandong University
  Jinan, Shandong, China Recruiting
• Qilu Hospital of Shandong University
  Jinan, Shandong, China Not yet recruiting

Study contacts

• Study coordinator: Yueyue Li
• Email: lyynqj@126.com
• Phone: 18560089751

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dual vonoprazan and amoxicillin therapy for Helicobacter pylori infection in Uruguay

  This trial tests whether a two-drug regimen (vonoprazan and amoxicillin for 14 days) can be as effective as the standard four-drug regimen for eradicating H. pylori in adults in Uruguay, with fewer side effects.

  Recruiting at 3 sites Phase 4 Hospital de Clínicas Dr. Manuel Quintela · Maldonado, Departamento de Maldonado and 3 other locations · NCT07924098

• Dual-drug therapy with linlarase glutarate and amoxicillin vs bismuth quadruple therapy for first-line Helicobacter pylori eradication

  This trial tests whether a dual-drug regimen of linlarase glutarate capsules plus amoxicillin can match the effectiveness of a standard bismuth-containing quadruple therapy for first-line Helicobacter pylori eradication.

  Recruiting at 24 sites Phase 4 Xijing Hospital of Digestive Diseases · Zhengzhou, Henan and 23 other locations · NCT07897994

• Feasibility of FFPE qPCR to Detect H. pylori and Clarithromycin Resistance

  This study tests whether tissue samples already collected during gastroscopy can be used with qPCR to find Helicobacter pylori and its clarithromycin resistance.

  Recruiting Clinique Bizet · Paris · NCT07821294

• Adding bismuth to vonoprazan‑amoxicillin therapy for H. pylori

  This study will test whether adding bismuth to a 14-day vonoprazan‑amoxicillin regimen improves H. pylori cure rates in adults who have never had eradication therapy.

  Recruiting Phase 3 National Taiwan University Hospital · Taipei · NCT07576959

• Endoscopic screening for H. pylori, intestinal metaplasia, and Barrett's mucosa during screening colonoscopy

  This project will try adding a gastroscopy with biopsies to routine screening colonoscopy to see how often H. pylori and early stomach changes appear in adults without upper GI symptoms.

  Recruiting Sigmund Freud PrivatUniversitat · Vienna · NCT07346521

• Treating H. pylori infection to help metabolic syndrome by changing gut bacteria.

  This study will see if adding a probiotic or berberine to standard H. pylori treatment helps adults with H. pylori infection and newly diagnosed metabolic syndrome improve blood sugar, cholesterol, weight, and other metabolic measures.

  Recruiting Phase 4 Nanjing First Hospital, Nanjing Medical University · Nanjing, Jiangsu · NCT07306988

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.